Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANI Pharmaceuticals

66.30
-5.2300-7.31%
Post-market: 66.300.00000.00%19:06 EDT
Volume:756.75K
Turnover:51.64M
Market Cap:1.43B
PE:-63.57
High:77.00
Open:76.01
Low:65.96
Close:71.53
Loading ...

ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

GlobeNewswire
·
20 Feb

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

StockStory
·
19 Feb

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

GlobeNewswire
·
19 Feb

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Zacks
·
17 Feb

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Zacks
·
17 Feb

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Zacks
·
17 Feb

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

StockStory
·
14 Feb

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

StockStory
·
13 Feb

Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now?

Zacks
·
31 Jan

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Zacks
·
31 Jan

Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain

Simply Wall St.
·
30 Jan

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

GlobeNewswire
·
29 Jan

ANI Pharmaceuticals (ANIP) Receives a Buy from Raymond James

TIPRANKS
·
17 Jan

Stock Track | ANI Pharmaceuticals Soars 5% on Leerink Partners' Buy Rating Reaffirmation

Stock Track
·
15 Jan

Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?

Zacks
·
15 Jan

Leerink Partners Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
15 Jan

Alcami Announces CEO Transition

THOMSON REUTERS
·
14 Jan

Press Release: Alcami Announces CEO Transition

Dow Jones
·
14 Jan

Ani Pharmaceuticals Sees Fiscal 2024 Adjusted EPS, Revenue at or Above Guidance; Sets Fiscal 2025 Revenue Outlook

MT Newswires Live
·
13 Jan

ANI Pharmaceuticals Inc - Expects 2025 Net Revenues of $739M-$759M

THOMSON REUTERS
·
13 Jan